Xeris Biopharma Holdings Inc (0A8E.L)

Name: Xeris Biopharma Holdings Inc Financial Statements
Creator: Quarter Results

Healthcare | Biotechnology

Latest reporting period: 2025-09-30

Latest Quarter

2025-09-30

Revenue

$74.4M

Net Income

$621K

Operating Margin

9.0%

Free Cash Flow

-$37.8M

Debt / Assets

109.2%

Values are in USD and rounded to the nearest whole number unless noted.

Swipe horizontally to view all columns.

Income statement quarterly history for Xeris Biopharma Holdings Inc (0A8E.L).
Income Statement (Quarterly)	2025-09-30	2025-06-30	2025-03-31	2024-12-31
Revenue	74,380,000	71,539,000	60,119,000	60,099,000
Cost of Revenue	10,996,000	14,609,000	8,728,000	9,478,000
Gross Profit	63,384,000	56,930,000	51,391,000	50,621,000
Operating Expenses
R&D Expenses	0	0	0	0
SG&A Expenses	46,459,000	44,393,000	44,018,000	40,139,000
Operating Expenses	56,653,000	52,448,000	54,481,000	48,942,000
Operating Income	6,731,000	4,482,000	-3,090,000	1,679,000
Interest Expense	7,268,000	7,358,000	7,305,000	7,703,000
Income Before Tax	621,000	-1,928,000	-9,220,000	-5,113,000
Income Tax Expense	0	0	0	0
Net Income	621,000	-1,928,000	-9,220,000	-5,113,000
Per Share
EPS	0.00	-0.01	-0.06	-0.03
EPS Diluted	0.00	0.00	0.00	0.00

Income statement annual history for Xeris Biopharma Holdings Inc (0A8E.L).
Income Statement (Annual)	2024-12-31	2023-12-31	2022-12-31
Revenue	203,070,000	163,914,000	110,248,000
Cost of Revenue	36,832,000	28,645,000	22,634,000
Gross Profit	166,238,000	135,269,000	87,614,000
Operating Expenses
R&D Expenses	0	0	0
SG&A Expenses	163,481,000	146,095,000	137,745,000
Operating Expenses	199,884,000	179,279,000	169,554,000
Operating Income	-33,646,000	-44,010,000	-81,940,000
Interest Expense	33,175,000	26,609,000	15,325,000
Income Before Tax	-57,104,000	-63,504,000	-96,084,000
Income Tax Expense	-2,268,000	-1,249,000	-1,424,000
Net Income	-54,836,000	-62,255,000	-94,660,000
Per Share
EPS	-0.37	-0.45	-0.70
EPS Diluted	0.00	0.00	0.00

Balance sheet quarterly history for Xeris Biopharma Holdings Inc (0A8E.L).
Balance Sheet (Quarterly)	2024-12-31	2023-12-31	2022-12-31
Assets
Cash and Cash Equivalents	71,621,000	67,449,000	121,966,000
Short Term Investments	0	5,002,000	0
Net Receivables	40,415,000	39,197,000	30,830,000
Inventory	48,175,000	38,838,000	24,735,000
Total Current Assets	167,662,000	156,264,000	186,818,000
Property Plant Equipment	28,211,000	29,175,000	28,375,000
Goodwill and Intangibles	121,780,000	132,623,000	124,599,000
Total Assets	323,060,000	322,602,000	344,522,000
Liabilities
Account Payables	2,290,000	11,565,000	4,606,000
Short Term Debt	21,182,000	3,495,000	1,580,000
Total Current Liabilities	100,443,000	95,193,000	73,621,000
Long Term Debt	250,265,000	225,696,000	196,477,000
Total Liabilities	352,675,000	329,384,000	299,335,000
Shareholders Equity
Retained Earnings	-671,861,000	-617,025,000	-554,770,000
Total Shareholders Equity	-29,615,000	-6,782,000	45,187,000

Balance sheet annual history for Xeris Biopharma Holdings Inc (0A8E.L).
Balance Sheet (Annual)	2024-12-31	2023-12-31	2022-12-31
Assets
Cash and Cash Equivalents	71,621,000	67,449,000	121,966,000
Short Term Investments	0	5,002,000	0
Net Receivables	40,415,000	39,197,000	30,830,000
Inventory	48,175,000	38,838,000	24,735,000
Total Current Assets	167,662,000	156,264,000	186,818,000
Property Plant Equipment	28,211,000	29,175,000	28,375,000
Goodwill and Intangibles	121,780,000	132,623,000	124,599,000
Total Assets	323,060,000	322,602,000	344,522,000
Liabilities
Account Payables	2,290,000	11,565,000	4,606,000
Short Term Debt	21,182,000	3,495,000	1,580,000
Total Current Liabilities	100,443,000	95,193,000	73,621,000
Long Term Debt	250,265,000	225,696,000	196,477,000
Total Liabilities	352,675,000	329,384,000	299,335,000
Shareholders Equity
Retained Earnings	-671,861,000	-617,025,000	-554,770,000
Total Shareholders Equity	-29,615,000	-6,782,000	45,187,000

Cash flow quarterly history for Xeris Biopharma Holdings Inc (0A8E.L).
Cash Flow Statement (Quarterly)	2024-12-31	2023-12-31	2022-12-31
Operating Activities
Net Income	-54,836,000	-62,255,000	-94,660,000
Depreciation & Amortization	12,625,000	13,160,000	12,668,000
Stock Based Compensation	18,363,000	10,716,000	12,160,000
Change in Working Capital	-8,820,000	-6,294,000	-35,150,000
Operating Cash Flow	-36,981,000	-47,023,000	-102,891,000
Investing Activities
Capital Expenditure	-868,000	-2,263,000	-524,000
Investments	-868,000	-2,263,000	-524,000
Investing Cash Flow	4,883,000	-6,004,000	34,461,000
Financing Activities
Debt Repayment	38,169,000	0	102,718,000
Common Stock Issued/Repurchased	-3,734,000	-1,009,000	29,532,000
Dividends Paid	0	0	0
Financing Cash Flow	36,168,000	-1,613,000	127,473,000
Summary
Free Cash Flow	-37,849,000	-49,286,000	-103,415,000
Net Change in Cash	4,070,000	-54,640,000	59,043,000

Cash flow annual history for Xeris Biopharma Holdings Inc (0A8E.L).
Cash Flow Statement (Annual)	2024-12-31	2023-12-31	2022-12-31
Operating Activities
Net Income	-54,836,000	-62,255,000	-94,660,000
Depreciation & Amortization	12,625,000	13,160,000	12,668,000
Stock Based Compensation	18,363,000	10,716,000	12,160,000
Change in Working Capital	-8,820,000	-6,294,000	-35,150,000
Operating Cash Flow	-36,981,000	-47,023,000	-102,891,000
Investing Activities
Capital Expenditure	-868,000	-2,263,000	-524,000
Investments	-868,000	-2,263,000	-524,000
Investing Cash Flow	4,883,000	-6,004,000	34,461,000
Financing Activities
Debt Repayment	38,169,000	0	102,718,000
Common Stock Issued/Repurchased	-3,734,000	-1,009,000	29,532,000
Dividends Paid	0	0	0
Financing Cash Flow	36,168,000	-1,613,000	127,473,000
Summary
Free Cash Flow	-37,849,000	-49,286,000	-103,415,000
Net Change in Cash	4,070,000	-54,640,000	59,043,000